Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price24.67 USD
Fair value30.77
Our investment reviews on this name
2026-10-02Read Distribution24.67+0.0% to today
2026-07-23Read Markup26.50-6.9% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Braze, Inc. holds its Distribution at $24.67. Consolidating, no directional conviction, held for 7 days.
As held on the ledger · 2026-09-24
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 7 days
Price at the screen
$24.67
Valuation
N/A trailing · 25.12 forward price to earnings
Values screen
PASS
Beta
0.88
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
3.02%
Below 33%
Interest-bearing debt is just 3.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
15.05%
Below 33%
Cash held in interest-bearing accounts and securities is 15.0% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Braze, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-24 screen. The gold marker is the market price at the same screen. A 24.7% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus None. The average target sits +46% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-24 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Braze powers app messages yet stays unprofitable
Every time a fitness app nudges a user back with a tailored message or a retailer reminds someone about an abandoned cart, Braze often sits behind the flow. Revenue is rising 30% a year, a solid clip that sets it apart from many slowing software names.
Even so the business carries a 16% negative profit margin and negative 23% return on equity, with only a weak moat protecting its position. Forward earnings sit at 27 times while our fair value of $28.85 offers just a 9% margin of safety above the current $26.50 price.
Analyst targets cluster around $32 yet the thin competitive edge and persistent losses point to a name best observed rather than held. Ethical screen raises no flags.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BRZE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. Since the last review it entered the Tech 100; its composite score rose.
2026-09-08Markup$31.96+0.0%Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06Markup$31.96+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-05Markup$31.96+9.8%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-04Markup$29.12+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-03Markup$29.12+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-02Markup$29.12+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-01Markup$29.12+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$29.12+9.9%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35.
2026-07-23Markup$26.50+15.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.7% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it strong buy, with a mean price target of $35.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
